GlassScriptPhysician profile
Michelle Fielding
NPI 1477013589
$2,327.76
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $990 · 2022: $1,116 · 2023: $223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $222.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $357.52 | 2021-2023 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $344.56 | 2021-2023 | Breztri |
| Regeneron Healthcare Solutions, INC. | $284.64 | 2021-2023 | Dupixent |
| Abbvie INC. | $210.04 | 2021-2022 | |
| Novo Nordisk INC | $186.97 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $166.54 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $142.09 | 2021-2023 | Relistor, Xifaxan |
| Jazz Pharmaceuticals INC. | $140.51 | 2021-2022 | |
| Mylan Specialty L.P. | $109.02 | 2021-2023 | Yupelri |
| Lilly USA, LLC | $78.26 | 2021-2022 | |
| Grifols USA, LLC | $52.57 | 2021-2022 | |
| Pulmonx Corporation | $40.30 | 2022 | |
| Janssen Pharmaceuticals, INC | $38.65 | 2023 | Spravato |
| Electromed, INC. | $29.64 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.47 | 2021-2023 | Spiriva Respimat, Stiolto Respimat |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $21.01 | 2022 | |
| Novartis Pharmaceuticals Corporation | $19.14 | 2022 | |
| Hikma Pharmaceuticals USA | $17.04 | 2021 | |
| Eyevance Pharmaceuticals LLC | $17.04 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $14.47 | 2021 | |
| Axsome Therapeutics, INC. | $14.18 | 2023 | Sunosi |
| Kowa Pharmaceuticals America, INC. | $14.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Fielding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.